Inari Medical price target raised to $60 from $47 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Inari Medical to $60 from $47 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results in the MedTech sector. Across the market cap, there continues to be crowding in the strongest growth stories with a widening performance and valuation gap between “haves” and “have nots”, but while this could create some profit-taking, dips in these names will get bought if fundamentals are moving in the right direction, the analyst tells investors in a research note. For Inari Medical, Truist is looking for low-to-mid single digit revenue beat in Q2 with at least some upside coming from core U.S. VTE, or venous thromboembolism, in addition to emerging therapies and international business, the firm added.